Ionis to host expert panel discussion on sHTG
Ionis Pharmaceuticals (NASDAQ: IONS) has announced a webinar focused on severe hypertriglyceridemia (sHTG), scheduled for Monday, April 14 at 11:00 a.m. ET. The event will feature an expert panel discussion addressing the risks, clinical presentation, and significant unmet medical needs associated with sHTG.
The panel will be led by Dr. Sam Tsimikas, senior vice president of global cardiovascular development at Ionis, and includes distinguished experts in lipidology, cardiology, and endocrinology:
- Dr. Seth Baum - Chief Medical Officer, Flourish Research
- Dr. Alan S. Brown - Director, Lipid Clinic at Advocate Lutheran General Hospital
- Dr. Savitha Subramanian - Medical Director, Lipid Clinic at University of Washington Medical Center
The webinar will be accessible through the company's investor relations website, with a replay available for a time.
Ionis Pharmaceuticals (NASDAQ: IONS) ha annunciato un webinar incentrato sulla ipertrigliceridemia grave (sHTG), programmato per lunedì 14 aprile alle 11:00 ET. L'evento presenterà una discussione con un panel di esperti che affronterà i rischi, la presentazione clinica e i significativi bisogni medici insoddisfatti associati alla sHTG.
Il panel sarà guidato dal Dr. Sam Tsimikas, vicepresidente senior dello sviluppo cardiovascolare globale di Ionis, e includerà esperti di spicco in lipidologia, cardiologia ed endocrinologia:
- Dr. Seth Baum - Chief Medical Officer, Flourish Research
- Dr. Alan S. Brown - Direttore, Lipid Clinic presso l'Advocate Lutheran General Hospital
- Dr. Savitha Subramanian - Direttore medico, Lipid Clinic presso il University of Washington Medical Center
Il webinar sarà accessibile attraverso il sito web delle relazioni con gli investitori dell'azienda, con una registrazione disponibile per un periodo di tempo.
Ionis Pharmaceuticals (NASDAQ: IONS) ha anunciado un seminario web centrado en la hipertrigliceridemia severa (sHTG), programado para el lunes 14 de abril a las 11:00 a.m. ET. El evento contará con una discusión de un panel de expertos que abordará los riesgos, la presentación clínica y las importantes necesidades médicas no satisfechas asociadas con la sHTG.
El panel estará dirigido por el Dr. Sam Tsimikas, vicepresidente senior de desarrollo cardiovascular global en Ionis, e incluirá a distinguidos expertos en lipidología, cardiología y endocrinología:
- Dr. Seth Baum - Director Médico, Flourish Research
- Dr. Alan S. Brown - Director, Lipid Clinic en el Advocate Lutheran General Hospital
- Dr. Savitha Subramanian - Directora Médica, Lipid Clinic en el University of Washington Medical Center
El seminario web será accesible a través del sitio web de relaciones con inversores de la empresa, con una repetición disponible por un tiempo.
아이오니스 제약 (NASDAQ: IONS)은 심각한 고트리글리세리드혈증(sHTG)에 초점을 맞춘 웨비나를 발표했으며, 이는 4월 14일 월요일 오전 11시(ET)에 예정되어 있습니다. 이 행사에서는 sHTG와 관련된 위험, 임상적 증상 및 중요한 미충족 의료 필요성을 다루는 전문가 패널 토론이 진행됩니다.
패널은 Dr. Sam Tsimikas가 이끌며, 아이오니스의 글로벌 심혈관 개발 수석 부사장으로 활동하고 있으며, 지질학, 심장학 및 내분비학 분야의 저명한 전문가들이 포함됩니다:
- Dr. Seth Baum - Flourish Research의 최고 의료 책임자
- Dr. Alan S. Brown - Advocate Lutheran General Hospital의 지질 클리닉 소장
- Dr. Savitha Subramanian - University of Washington Medical Center의 지질 클리닉 의료 책임자
웨비나는 회사의 투자자 관계 웹사이트를 통해 접근 가능하며, 일정 기간 동안 다시 볼 수 있습니다.
Ionis Pharmaceuticals (NASDAQ: IONS) a annoncé un webinaire axé sur l'hypertriglycéridémie sévère (sHTG), prévu pour le lundi 14 avril à 11h00 ET. L'événement comprendra une discussion d'un panel d'experts abordant les risques, la présentation clinique et les besoins médicaux importants non satisfaits associés à la sHTG.
Le panel sera dirigé par Dr. Sam Tsimikas, vice-président senior du développement cardiovasculaire mondial chez Ionis, et comprendra des experts de renom en lipidologie, cardiologie et endocrinologie :
- Dr. Seth Baum - Directeur médical, Flourish Research
- Dr. Alan S. Brown - Directeur, Lipid Clinic à l'Advocate Lutheran General Hospital
- Dr. Savitha Subramanian - Directrice médicale, Lipid Clinic au University of Washington Medical Center
Le webinaire sera accessible via le site web des relations avec les investisseurs de l'entreprise, avec une rediffusion disponible pendant un certain temps.
Ionis Pharmaceuticals (NASDAQ: IONS) hat ein Webinar angekündigt, das sich auf schwere Hypertriglyceridämie (sHTG) konzentriert und für Montag, den 14. April um 11:00 Uhr ET geplant ist. Die Veranstaltung wird eine Expertenpanel-Diskussion umfassen, die sich mit den Risiken, der klinischen Präsentation und den erheblichen ungedeckten medizinischen Bedürfnissen im Zusammenhang mit sHTG beschäftigt.
Das Panel wird von Dr. Sam Tsimikas, Senior Vice President für globale kardiovaskuläre Entwicklung bei Ionis, geleitet und umfasst angesehene Experten in Lipidologie, Kardiologie und Endokrinologie:
- Dr. Seth Baum - Chief Medical Officer, Flourish Research
- Dr. Alan S. Brown - Direktor der Lipidklinik am Advocate Lutheran General Hospital
- Dr. Savitha Subramanian - Medizinischer Direktor der Lipidklinik am University of Washington Medical Center
Das Webinar wird über die Investor-Relations-Website des Unternehmens zugänglich sein, mit einer Wiederholung, die für eine bestimmte Zeit verfügbar ist.
- None.
- None.
– Webinar scheduled for Monday, April 14 at 11:00 a.m. ET –
- Seth Baum, M.D., MASPC, FACC, FAHA, FNLA chief medical officer, Flourish Research and clinical affiliate professor of cardiology, Florida Atlantic University
- Alan S. Brown, M.D., FNLA, director, Lipid Clinic, Advocate Lutheran General Hospital and adjunct clinical professor of medicine, Rosalind Franklin University of Medicine and Science
- Savitha Subramanian, M.D., medical director, Lipid Clinic and professor of medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington Medical Center
The webinar may be accessed at https://ir.ionis.com/events. A replay will be available for a limited time.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250403177425/en/
Ionis Investor Contact:
D. Wade Walke, Ph.D. – IR@ionis.com – 760-603-2331
Ionis Media Contact:
Hayley Soffer – media@ionis.com – 760-603-4679
Source: Ionis Pharmaceuticals, Inc.
FAQ
When is Ionis (IONS) hosting the sHTG expert panel webinar?
Who are the key speakers at the Ionis (IONS) sHTG webinar?
What topics will be covered in the Ionis (IONS) sHTG webinar?
How can investors access the Ionis (IONS) sHTG webinar?
